| 5.355 0.005 (0.09%) | 04-29 11:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.94 | 1-year : | 7.59 |
| Resists | First : | 5.94 | Second : | 6.5 |
| Pivot price | 5.57 |
|||
| Supports | First : | 5.05 | Second : | 4.2 |
| MAs | MA(5) : | 5.22 |
MA(20) : | 5.63 |
| MA(100) : | 9.97 |
MA(250) : | 11.46 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 16.2 |
D(3) : | 11.6 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 14.31 | Low : | 5.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LNSR ] has closed above bottom band by 23.4%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.47 - 5.49 | 5.49 - 5.51 |
| Low: | 5.15 - 5.18 | 5.18 - 5.2 |
| Close: | 5.31 - 5.34 | 5.34 - 5.39 |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Sun, 26 Apr 2026
LENSAR (LNSR) price target decreased by 32.00% to 8.67 - MSN
Wed, 22 Apr 2026
LNSR LENSAR Inc. posts wider than expected Q4 2025 loss even as shares rise modestly in today’s trading. - Cổng thông tin điện tử tỉnh Tây Ninh
Thu, 16 Apr 2026
LENSAR Announces Upcoming Chief Financial Officer Transition - The Globe and Mail
Sat, 04 Apr 2026
How The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target Reset - Yahoo Finance
Wed, 01 Apr 2026
Lake Street upgrades Lensar stock rating to buy after merger termination - Investing.com
Wed, 18 Mar 2026
Alcon and Lensar Agree to Terminate Merger Agreement - VisionMonday.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 8.67e+006 (%) |
| Held by Institutions | 18.8 (%) |
| Shares Short | 717 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.008e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -58.7 % |
| Operating Margin | -116.1 % |
| Return on Assets (ttm) | -22.4 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 5.844e+007 % |
| Gross Profit (p.s.) | -4.25 |
| Sales Per Share | 70.11 |
| EBITDA (p.s.) | 2.73939e+007 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -2.38 |
| Dividend | 0 |
| Forward Dividend | 1.02e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|